Key result
Direct oral anticoagulants significantly reduced stroke, systemic embolism, and intracranial hemorrhage compared to vitamin K antagonists in patients with atrial fibrillation, though more evidence is needed for specific high-risk comorbidities.
Why the study?
Clear data were lacking regarding the use of direct oral anticoagulants in patients with atrial fibrillation who also present with various comorbidities and high-risk profiles.
Do direct oral anticoagulants reduce thromboembolic events and bleeding compared to vitamin K antagonists in patients with atrial fibrillation and high-risk comorbidities?
Do direct oral anticoagulants reduce thromboembolic events and bleeding compared to vitamin K antagonists in patients with atrial fibrillation and high-risk comorbidities?
Answers are grounded in this paper and cite their sources.
This review highlights that DOACs are generally safer and more effective than VKAs in high-risk AF patients with various comorbidities, while emphasizing the need for further research in specific understudied populations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ayhan et al. (2023) conducted a review in Atrial fibrillation with comorbidities. Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKA) / Warfarin was evaluated on Stroke, systemic embolism, and intracranial hemorrhage. Direct oral anticoagulants significantly reduced stroke, systemic embolism, and intracranial hemorrhage compared to vitamin K antagonists in patients with atrial fibrillation, though more evidence is needed for specific high-risk comorbidities.
Synapse has enriched 10 related papers. Consider them for comparative context: